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Since the introduction of the benchmark dose 
(BMD) by Crump (1984), there has been 
considerable discussion about the merits of 
this measure relative to the traditional no 
observed adverse effect level (NOAEL), origi-
nally introduced by Lehman and Fitzhugh 
(1954) as a point of departure (PoD) for 
establishing human exposure guidelines, 
expressed in the form of a reference dose 
(RfD) (Barnes and Dourson 1988).
In its simplest form, the RfD is determined 
by the formula RfD = PoD/UF, where the 
uncertainty factor (UF) denotes the com-
bined effect of inter- and intra    species differ-
ences, as well as other uncertainties associated 
with the available data (Dourson et al. 1996). 
Essentially the same approach is used to derive 
other exposure guidelines, such as the tolerable 
daily intake or acceptable daily intake, but here 
we use the term “RfD” to represent a human 
exposure guideline, regardless of the type of 
test agent or critical end point considered.
In practice, a lower confidence limit on the 
BMD (the BMDL) is used as the PoD when 
the BMD approach is invoked. The introduc-
tion of the BMD for non  cancer end points has 
increased comparability between approaches 
to estimate exposure guidelines for non  cancer 
and cancer agents. Currently, a single approach 
is generally recom  mended to derive the PoD, 
but differences exist in terms of how to pro-
ceed after the derivation of the PoD, depend-
ing on whether the agent is non  genotoxic 
or a genotoxic carcinogen [European Food 
Safety Authority (EFSA) 2005, 2009a; U.S. 
Environmental Protection Agency (EPA) 
2005]. Several authors have specifically sug-
gested that the BMDL may serve as a PoD for 
carcinogens and non  carcinogens alike, lead-
ing to an integrated approach to cancer and 
non  cancer risk assessment (Gaylor et al. 1999; 
National Research Council 2009).
Potential advantages of the BMDL rela  tive 
to the NOAEL include the use of all available 
data in its determination and avoidance of the 
restriction that it be equal to one of the exper-
imental doses. Although the BMD concept 
is best developed for quantal response data 
(i.e., presence or absence of a given response), 
methods have also been developed for con-
tinuous response data (Gaylor et al. 1998; 
Murrell et al. 1998; Sand et al. 2006; Slob 
2002; Slob and Pieters 1998), and default 
approaches for applying the BMD concept 
for either type of response data have been 
suggested (EFSA 2009a; U.S. EPA 2000). 
[For more information on approaches for 
continuous and quantal data and a detailed 
comparison of the BMD vs. NOAEL, see 
EFSA (2009a) and Sand et al. (2008).]
In the past, the BMD method was 
employed primarily by regulatory authori-
ties in the United States, such as the U.S. 
EPA. However, the EFSA (2009a) recently 
released a scientific opinion that recom  mends 
the BMD approach for setting human expo-
sure guidelines, which has increased use of the 
BMD in risk assessments performed by the 
EFSA (2009b, 2009c, 2010).
A crucial aspect of the BMD method is 
the specification of the benchmark response 
(BMR) level associated with the BMD. For 
quantal data, the BMD with BMDL was 
originally presented as the dose causing an 
excess risk in the range of 1–10% (Crump 
1984; Kimmel and Gaylor 1988). In its opin-
ion on the BMD, the EFSA (2009a) argued 
that the BMR should ideally represent an 
effect size that is negligible or non  adverse, 
with the practical constraint that the BMR 
cannot be set at levels that are so low (or high) 
that estimation of the BMD requires extrapo-
lation beyond the range of the experimental 
data, in which case the result may be highly 
model dependent. Therefore, for quantal data 
representing severe lesions, the desirable or 
acceptable risk level is often much lower than 
what could be employed as a BMR, given the 
practical constraints of the data.
The issue of what BMR may be appropri-
ate as a starting point has been addressed to a 
Address correspondence to S. Sand, National Food 
Administration, P.O. Box 622, SE-751 26 Uppsala, 
Sweden. Telephone: 46-18-17-5335. Fax: 46-18-10-
5848. E-mail: Salomon.Sand@slv.se.
*Current address: National Center for Environmental 
Health, Agency for Toxic Substances and Disease 
Registry, Atlanta, GA, USA.
Supplemental Material is available online (http://
dx.doi.org/10.1289/ehp.1003327).
This research was conducted in part while S.S. 
was a visiting scientist at the McLaughlin Centre 
for Population Health Risk Assessment in 2009 and 
2010. D.K. is the Natural Sciences and Engineering 
Research Council of Canada Chair in Risk Science at 
the University of Ottawa.
The authors declare they have no actual or potential 
competing financial interests.
Received 10 December 2010; accepted 3 August 
2011.
A Signal-to-Noise Crossover Dose as the Point of Departure for 
Health Risk Assessment
Salomon Sand,1,2 Christopher J. Portier,3* and Daniel Krewski2,4
1Risk Benefit Assessment Department, National Food Administration, Uppsala, Sweden; 2McLaughlin Centre for Population Health Risk 
Assessment, University of Ottawa, Ottawa, Ontario, Canada; 3National Institute of Environmental Health Sciences, National Institutes of 
Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA; 4Risk Sciences International, Ottawa, 
Ontario, Canada
Ba c k g r o u n d: The U.S. National Toxicology Program (NTP) cancer bio  assay database provides 
an opportunity to compare both existing and new approaches to determining points of departure 
(PoDs) for establishing reference doses (RfDs).
oBjectives: The aims of this study were a) to investigate the risk associated with the traditional 
PoD used in human health risk assessment [the no observed adverse effect level (NOAEL)]; b) to 
present a new approach based on the signal-to-noise crossover dose (SNCD); and c) to compare the 
SNCD and SNCD-based RfD with PoDs and RfDs based on the NOAEL and benchmark dose 
(BMD) approaches.
Me t h o d s : The complete NTP database was used as the basis for these analyses, which were per-
formed using the Hill model. We determined NOAELs and estimated corresponding extra risks. 
Lower 95% confidence bounds on the BMD (BMDLs) corresponding to extra risks of 1%, 5%, 
and 10% (BMDL01, BMDL05, and BMDL10, respectively) were also estimated. We introduce the 
SNCD as a new PoD, defined as the dose where the additional risk is equal to the “background 
noise” (the difference between the upper and lower bounds of the two-sided 90% confidence inter-
val on absolute risk) or a specified fraction thereof.
re s u l t s: The median risk at the NOAEL was approximately 10%, and the default uncertainty fac-
tor (UF = 100) was considered most applicable to the BMDL10. Therefore, we chose a target risk 
of 1/1,000 (0.1/100) to derive an SNCD-based RfD by linear extrapolation. At the median, this 
approach provided the same RfD as the BMDL10 divided by the default UF.
co n c l u s i o n s: Under a standard BMD approach, the BMDL10 is considered to be the most appro-
priate PoD. The SNCD approach, which is based on the lowest dose at which the signal can be reli-
ably detected, warrants further development as a PoD for human health risk assessment.
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certain extent by studies that have compared 
actual NOAEL and BMDL values across sev-
eral data sets. Results suggest that the aver-
age risk at the NOAEL may be in the range 
of 5–10% (Allen et al. 1994b; Fowles et al. 
1999) or even > 10% (Allen et al. 1994a), 
and use of a BMR in this range has been sug-
gested. The U.S. EPA has used an extra risk 
of 10% as a default (with the exception of 
develop  mental toxicity data, where an extra 
risk of 5% has been applied), and the EFSA 
also recommends a default BMR (extra risk) 
of 10% for quantal data, with modification 
based on statistical or toxicological considera-
tions as needed (EFSA 2009a).
The derivation of a PoD under a dose–
response modeling approach is closely related 
to the selection of the BMR. We investigated 
the question of which BMR is most closely 
associated with the traditional PoD—the 
NOAEL—in detail using an analy  sis that 
provides a benchmark against which new 
approaches can be compared. Motivated in 
part by practical constraints on the lower 
end of the range of possible BMR values, 
we present a new strategy for derivation of 
the PoD based on the concept of a signal-to-
noise crossover dose (SNCD). The SNCD is 
defined as the dose at which the additional 
risk equals the “background noise” or some 
fraction (e.g., 0.67) of the noise, where “back-
ground noise” is defined as the difference 
between the upper and lower bounds of the 
two-sided 90% confidence interval (CI) on 
absolute risk. The SNCD thus provides an 
estimate of the lowest dose that can be derived 
as a PoD for risk assessment without low-dose 
extrapolation. The SNCD is compared with 
typical target PoDs, specifically, the BMDLs 
corresponding to extra risks of 1%, 5%, and 
10% (BMDL01, BMDL05, and BMDL10, 
respectively) and the NOAEL. In addition, 
we describe an approach for deriving an RfD 
using the SNCD as the PoD and compare 
the resulting RfD to RfDs derived from the 
NOAEL and BMDL. We used the complete 
U.S. National Toxicology Program (NTP) 
database on 2-year carcinogen bio  assays in 
rats and mice (NTP 2009) as the basis for 
these analyses. 
Materials and Methods
Databases. We used data from the U.S. 
NTP 2-year rodent toxicology and carcino-
genesis studies to evaluate the different PoDs 
and RfDs. Since 1981 the NTP has directed 
a rodent carcinogenicity bio  assay program 
begun by the National Cancer Institute (NCI). 
Together the NCI and NTP have conducted 
> 500 cancer studies. Most of these studies fol-
low a relatively common protocol, with male 
and female rats and mice tested at a control 
and three dose levels for each test agent (Bucher 
and Portier 2004; Chhabra et al. 1990).
Data were abstracted on 13–14 January 
2009 from the Toxicology Database 
Management  System  (TDMS)  and 
Carcinogenesis Bioassay Data System (NTP 
2009). Only studies marked as “chronic” in 
the TDMS were included (204 rat studies 
and 192 mouse studies). Individual animals 
were excluded from the data set if they were 
designated as “interim/scheduled sacrifice,” 
“missing,” “wrong sex,” and “other,” and dose 
groups that were marked as sentinel (SEN) or 
restricted diet (RTD) were excluded. As in the 
regular NTP technical reports summarizing 
the study results, all dose groups with the same 
concentration values (other than stop-dose 
groups) were automatically merged. Stop-dose 
groups were excluded from trend statistics but 
were included in pairwise statistics.
Data selection. The data generated as 
described above were considered for inclu-
sion in the present analysis if they satisfied the 
following three criteria: a) The data for the 
end point demonstrated a significantly increas-
ing dose–response trend according to the NTP 
poly3 p-value for trend (p ≤ 0.05); b) the NTP 
determined that the end point demonstrated 
“some” or “clear” evidence of carcinogenic-
ity; and c) the data for the end point dem-
onstrated a NOAEL according to the NTP 
poly3 p-value (p > 0.05). (Within a given 
data set, the highest non  significant dose was 
regarded as the NOAEL for that data set.) 
These criteria resulted in the initial selection 
of 1,383 individual data sets. We excluded 
any stop doses and excluded data sets describ-
ing combinations of morphology codes (e.g., 
“adenoma and carcinoma”) if the combined 
response was ascribed only to the observed 
response associated with a specific morphol-
ogy code (e.g., “adenoma” response but zero 
“carcinoma” response) already accounted 
for in the data selection. These refinements 
yielded 1,128 data sets spanning 140 technical 
reports. The number of individual data sets 
in the 140 reports ranged from 1 to 53, with 
a median number of 6. Results presented in 
the present study are based on the data sets 
fulfilling the requirements discussed above 
(1,128 data sets), along with standard require-
ments for BMD analysis, as described below.
Model fitting. The dose–response data 
were fitted with the Hill model by maximum 
likelihood; both three- and two-parame-
ter versions of the model were considered. 
Data sets demonstrating a significant dose–
response trend and adequate goodness 
of fit (both p ≤ 0.05, consistent with stan-
dard data set requirements for calculating a 
BMD) were included in the analyses, leav-
ing a total of 786 data sets. For a subset of 
these data, model dependence was investi-
gated by contrasting Hill model results with 
estimates from a Weibull model. Technical 
details regarding the models, the model 
fitting, the model selection process, and the 
analysis of model dependence are provided 
in Supplemental Material, Section 1 (http://
dx.doi.org/10.1289/ehp.1003327).
The risk at the PoD. Using the profile 
likeli  hood method, the upper (one-sided) 95% 
confidence bound on the extra risk (UER) at a 
given dose, d, will, if used as the BMR in a 
standard BMD analysis, result in a BMDL 
that equals dose d (i.e., if the BMDL is defined 
as the lower one-sided 95% confidence bound 
on the BMD and is estimated under the profile 
likelihood method). We used the fitted Hill 
model to obtain a point estimate, as well as an 
upper 95% confidence bound, on extra risk at 
the NOAEL for each data set. The upper 95% 
confidence bound on extra risk (UER) at the 
NOAEL (UERNOAEL)   (estimated using the 
profile likelihood method) was compared with 
standard BMRs (extra risks) of 1%, 5%, and 
10% used in BMD analysis.
A central estimate of the UERNOAEL may 
be regarded as a reflection of the typical level 
of risk associated with the traditional PoD 
used in risk assessment. Extra risk calculations 
identical to those described for the NOAEL 
were also performed for the SNCD.
The signal-to-noise crossover dose. The 
SNCD is defined as the dose where the point 
estimate of additional risk is equal to or, 
alternatively, 0.67× the (absolute) difference 
between the upper and lower bound of a two-
sided 90% CI on absolute risk at that dose. In 
the process of estimating the SNCD, a signal-
to-noise ratio (SNR) was defined as
  SNR = [p(d) – p(0)]/(P95 – P05),  [1]
where p(d) – p(0) is the point estimate of addi-
tional risk at dose d, and P95 – P05 is the dif-
ference between the upper 95th and lower 5th 
confidence bound on absolute risk at dose d. 
We defined two SNCDs, the SNCD1.0 (cor-
responding to a critical SNR of 1) and the 
SNCD0.67 (corresponding to an SNR of 0.67). 
We estimated the SNCD using the profile 
likelihood method, by evaluating the SNR 
at progressively lower doses until the critical 
SNR was reached (the SNR approaches zero 
when the dose approaches zero), as illustrated 
conceptually in Figure 1. Technical details, 
including a description of the algorithm 
used for deriving the SNCD, are provided 
in Supplemental Material, Section 2 (http://
dx.doi.org/10.1289/ehp.1003327). 
If the SNCD was outside of the experi-
mental dose range for a data set (i.e., the 
SNCD was higher than the highest dose), the 
data set was not used for SNCD estimation. 
Therefore, the SNCD1.0 was derived for only 
439 data sets, and the SNCD0.67 was derived 
for 665 data sets. In contrast, the BMDL10 was 
lower than the highest dose for 694 data sets 
[the point estimate (BMD10) was lower than Sand et al.
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the highest dose for 546 data sets], and the 
NOAEL was lower than the highest dose 
for 596 data sets. Under the model selection 
approach used [see Supplemental Material, 
Section 1 (http://dx.doi.org/10.1289/
ehp.1003327)], the three-parameter Hill 
model was selected for 62 data sets, including 
4 (6%) for which the SNCD1.0 was outside the 
experimental dose range, and the two-param-
eter Hill model was selected for 724 data sets, 
including 343 (47%) with SNCD1.0 outside 
of the experi  mental range. The SNCD was 
less likely to be out of the experimental range 
for data sets modeled using a three-parameter 
model because these data sets usually had more 
pronounced dose responses.
In addition to calculating the SNCD, 
we also calculated a point estimate of the 
extra risk at the SNCD and an upper (one-
sided) 95% confidence bound on extra risk 
at the SNCD (UERSNCD). This was done in 
a manner identical to that described above. 
The UERSNCD may be regarded as an objec-
tive estimate of the lowest practical BMR 
that may be used for a given data set. The 
SNCD1.0 and SNCD0.67 were compared with 
the NOAEL and BMDLs, corresponding to 
extra risks of 1%, 5%, and 10%, calculated 
for each data set for which these measures 
could be determined.
Establishment of human exposure guide-
lines. It has been debated whether or not the 
standard UFs used in risk assessment require 
modification when a BMDL is used as the 
PoD, rather than a NOAEL. The default UF 
of 10 × 10 = 100 allows for a possible 10-fold 
increased sensitivity in humans compared 
with experimental animals and for a 10-fold 
variation in susceptibility within the human 
population. The size of the UF covering such 
generally unknown variability is, in a strict 
sense, independent of the BMR used for deriv-
ing the PoD from experimental data, because 
the variability intended to be accounted for 
spans the entire dose range.
Within the construct of the BMD, the 
range of BMRs associated with the NOAEL 
appears to have been, in some sense, regarded 
as “acceptable.” The specification of a BMR 
under a quantitative dose–response model-
ing approach highlights the issue of whether 
or not an additional UF representing low-
dose extrapolation should be added, in addi-
tion to accounting for inter  species differences 
in sensitivity and inter    individual variability 
within the human population. This concerns 
the case of more severe lesions for which the 
“acceptable risk” is lower than the BMR value 
that can be used given the practical data limi-
tations; the UERSNCD may be regarded as 
an objective estimate of the lowest practical 
BMR for a given data set.
The choice of a specific UF to take into 
account the fact that the PoD is not risk 
free will be influenced by shape of the dose– 
response curve below the PoD. If the dose–
response curve is linear, this factor will reduce 
the BMR at the PoD proportionally, but 
non  linear approaches may also be envisioned. 
A fundamental reassessment of the UFs to 
be used is outside the scope of this article. 
For purposes of comparison of the NOAEL, 
BMDL, and SNCD as alternative PoDs, it 
is assumed that the standard UF of 100 is 
appropriate for establishing an RfD. For com-
parison purposes, we considered the standard 
UF of 100 to be most applicable to a BMDL 
corresponding to the median UERNOAEL 
(BMRm). Using an extra risk of BMRm would 
provide a similar level of risk protection as the 
traditional approach that uses a NOAEL as 
the PoD. Thus, in the present application of 
the BMD approach, the BMDL correspond-
ing to the BMRm is regarded as an appropri-
ate default PoD to which the current UFs 
can be applied for purposes of establishing a 
human exposure guideline.
Application of the default UF of 100 to 
the dose corresponding to the BMRm trans-
lates to a target (extra) risk of BMRm/100 in 
animals if the dose–response curve is linear 
below the PoD. Using the UERSNCD as the 
starting point, the RfD corresponding to a 
target risk of BMRm/100 under the assump-
tion of linearity is calculated as
  RfDSNCD = (BMRm/100)  
    × (SNCD/UERSNCD).  [2]
This definition implies that the UF applied to 
the SNCD will depend on the extra risk associ-
ated with the SNCD and is thus specific to the 
data set being analyzed. We used a target risk 
of BMRm/100 and a linear model to deter-
mine SNCD-based RfDs as a basis for com-
parisons with BMDL10- and NOAEL-based 
RfDs derived using a standard UF approach. 
However, alternative target risks and low-dose 
extrapolation models also may be considered 
under the SNCD approach.
Results
Risk at the NOAEL and the SNCD. 
Distributions of the UER at the NOAEL, 
SNCD1.0, and SNCD0.67 are shown in 
Figure 2. Table 1 presents medians and lower 
5th and upper 95th percentiles for the point 
estimate of extra risk, as well as the UER, at 
the NOAEL, SNCD1.0, and SNCD0.67. Based 
on the 786 selected data sets, the median of 
the UER at the NOAEL is 11%. The same 
median results when considering only the 
data set for which the NOAEL is lower than 
the highest dose (case 1b). Considering the 
665 data sets for which an SNCD0.67 was 
derived, the median extra risk and UER at 
the NOAEL are 7% and 12%, respectively 
(case 1c; Table 1). Considering the 439 
data sets for which the SNCD1.0 was derived, 
the median extra risk and UER at the NOAEL 
are higher: 9% and 14%, respectively (case 1d; 
Table 1). This indicates that the extra risk at 
the NOAEL is higher for data sets where an 
SNR ≥ 1 is observed within the experi  mental 
dose range (data sets with more pronounced 
dose–response relationships) compared with 
data sets where the signal is smaller than the 
noise (SNR < 1).
The median of the UER at SNCD1.0 
appears to be higher than that at the NOAEL 
(18% for SNCD1.0 case 1 vs. 14% for NOAEL 
case 1d; Table 1), whereas the median of the 
Figure 1. Estimation of the SNCD. (A) The Hill model fitted to data on liver cholangiocarcinoma observed in 
female Harlan Sprague-Dawley rats exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (solid curve) (NTP 2006). 
The dotted curves represent the two-sided 90% CI on absolute risk around the fitted model, as estimated by 
the profile likelihood method; circles represent observed responses (in this example, for six different doses) 
with 90% CIs. SNCD1.0 represents the dose (2,000 units) at which the additional risk (0.11 – 0 = 0.11 units: the 
signal) is equal to the (absolute) difference between the upper (0.17) and lower (0.06) bound on absolute 
risk (0.17 – 0.06 = 0.11 units: the noise). The SNCD1.0 corresponds to an SNR equal to 1 (0.11/0.11 = 1). (B) The 
relationship between dose and SNR. The SNR at a given dose d equals the point estimate of additional risk 
at d divided by the (absolute) difference between the upper 95th and lower 5th confidence bound on abso-
lute risk at d. The doses that correspond to SNRs of 1 and 0.67 are solved from the spline function as the 
SNCD1.0 and SNCD0.67, respectively.
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UER at SNCD0.67 appears to be lower than 
that at the NOAEL (7% for SNCD0.67 case 1 
vs. 12% NOAEL case 1c). Thus, the SNCD0.67 
and the SNCD1.0 bracket the NOAEL.
The UERs in Table 1 can be contrasted 
with standard BMRs (extra risk) of 1%, 5%, 
and 10%, typically employed in the BMD 
method. The UER at the NOAEL is > 1% 
(BMR > 0.01) in virtually all 786 data sets; it is 
> 5% for 90% of the data; and it is > 10% for 
54% of the data (Figure 2). The correspond-
ing values for the SNCDs are also given in 
Figure 2.
Table 1 also presents results for a subset of 
the selected data composed only of data sets 
with the lowest NOAEL across all end points 
considered in each selected technical report 
(case 2). This is intended to reflect the PoDs 
that would be likely considered in a practical 
risk assessment application. Only small dif-
ferences are observed relative to results for the 
full data set (case 1). The extra risk associated 
with the NOAEL and the SNCDs becomes 
lower for data sets that are more informative 
regarding responses in the low-dose region 
(median risk for case 4 < median risk for case 3; 
Table 1); this effect is more pronounced for the 
SNCD than for the NOAEL.
Comparison of the SNCD with the 
BMDL and NOAEL. The distributions 
of BMDL:SNCD1.0 ratios are shown in 
Figure 3, along with the distribution of the 
NOAEL:SNCD1.0 ratios. Similar results 
are presented for the SNCD0.67 in Figure 4. 
The median and lower 5th and upper 95th 
percentiles of these distributions are summa-
rized in Table 2. The BMDL01 is < SNCD1.0 
for all data sets; the BMDL05 is > SNCD1.0 
for 15% of the data sets; and the BMDL10 
is > SNCD1.0 for 33% of the data sets 
(Figure 3). The median NOAEL:SNCD1.0 
ratio is 1 (Table 2). The BMDL01  is 
< SNCD0.67 in virtually all data sets; the 
BMDL05 is > SNCD0.67 for 37% of the 
data sets; and the BMDL10 is > SNCD0.67 for 
61% of the data sets (Figure 4). The median 
NOAEL:SNCD0.67 ratio is 1.9 (Table 2). 
Results for the subset of data composed 
of only data sets with the lowest NOAEL in 
each NTP technical report (case 2; Table 2) are 
similar to those presented above for all data sets 
(case 1). The SNCD tends to decrease, relative 
to the other PoDs, for data sets that are more 
informative regarding responses in the low-dose 
region (i.e., median ratios for case 4 > median 
ratios for case 3; Table 2); this effect is more 
pronounced in the BMDL:SNCD ratios than 
in the NOAEL:SNCD ratios.
Correlations between differences in dose 
and risk. The median UER at the SNCD1.0 
is higher than that at the NOAEL (18% vs. 
11–14%; Table 1), although the median 
NOAEL:SNCD1.0 ratio is 1 (Table 2), 
which may appear contradictory. The asso-
ciation between the ratio of the UERs at the 
NOAEL and SNCD1.0, and the ratio of the 
SNCD1.0 and NOAEL per se, is depicted 
in graphical form in Figure 5, which shows 
that the median of both ratios is 1. Thus, 
although the median UER at the SNCD1.0 
and NOAEL differs (Table 1), the median 
ratio of the UERs is 1 (Figure 5A). This is due 
to differences in the shape of the respective 
UER distributions; the distribution is more 
Table 1. Extra risk at the NOAEL and the SNCD, expressed as medians and lower 5th (P05) and upper 95th 
(P95) percentiles across the n data sets considered.
Point estimate of extra risk UER 
PoD Casea n Median P05 P95 Median P05 P95
NOAEL 1 786 0.060 0.020 0.33 0.11 0.039 0.51
1b 596 0.063 0.018 0.37 0.11 0.036 0.56
1c 665 0.067 0.020 0.37 0.12 0.038 0.55
1d 439 0.089 0.022 0.42 0.14 0.040 0.60
2 133 0.061 0.022 0.43 0.11 0.038 0.63
3 330 0.086 0.020 0.45 0.14 0.036 0.64
4 456 0.055 0.022 0.17 0.096 0.040 0.28
SNCD1.0 1 439 0.11 0.026 0.44 0.18 0.038 0.63
2 106 0.13 0.025 0.39 0.21 0.038 0.56
3 217 0.19 0.028 0.50 0.30 0.040 0.73
4 222 0.062 0.026 0.29 0.098 0.038 0.46
SNCD0.67 1 665 0.042 0.013 0.23 0.073 0.021 0.41
2 124 0.045 0.013 0.25 0.083 0.021 0.41
3 243 0.11 0.010 0.33 0.19 0.018 0.57
4 422 0.029 0.013 0.12 0.047 0.022 0.23
aDifferent subsets of the 786 data sets were considered, as represented by the following cases. Case 1: All data sets 
adequate for dose–response modeling [according to the criteria in Supplemental Material, Section 1 (http://dx.doi.
org/10.1289/ehp.1003327)] and for which an SNCD was derived; all 786 data sets adequate for modeling were included 
for the NOAEL case. Case 1b: Data sets in case 1 for which the NOAEL was lower than the highest dose. Case 1c: 
Data sets in case 1 for which an SNCD0.67 was derived. Case 1d: Data sets in case 1 for which an SNCD1.0 was derived. 
Case 2: Data sets with the lowest NOAEL in each selected technical report included in case 1. Case 3: Data sets in 
case 1 including at most one dose for which the observed extra risk was > 0 and ≤ 0.2; the observed extra risk at a 
given dose, i, was calculated as [xi/ni – p(0)]/[1 – p(0)], where p(0) is the point estimate of the background risk. Case 4: 
Data sets in case 1 including more than one dose for which the observed extra risk was > 0 and ≤ 0.2. 
Figure 2. The UER at the NOAEL (A), SNCD1.0 (B), and SNCD0.67 (C). The percentages of data sets exceeding standard BMR (extra risk) levels of 0.01, 0.05, and 0.1 
are given.
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skewed to the left for the NOAEL rela  tive 
to the SNCD1.0 (Figure 2). The relationship 
between the BMDL10 and the NOAEL is 
portrayed in a similar fashion in Figure 5B. 
The circles in Figure 5B that are situated 
along the curved line correspond to data sets 
for which the Hill coefficient η = 1. Thus, 
the relation between the ratio of the UERs 
and the measurements themselves differs for 
data sets with η = 1 versus η > 1.
Establishment of an RfD based on the 
NOAEL, BMDL, and SNCD. The BMRm at 
the NOAEL was previously determined to be 
slightly above 10% (11–14%, depending on 
data set selection; Table 1). This is the general 
level of risk associated with the traditional 
PoD in risk assessment, given the range of 
study designs covered in this analysis. Thus, 
the application of a standard UF of 100 to 
the BMDL10 can be expected to lead to RfDs 
that are, on average, similar to those based on 
the NOAEL.
To compare RfDs based on the SNCD 
with RfDs based on the NOAEL and 
BMDL10, we assumed that the dose–response 
curve is linear below the PoD and that the 
RfD corresponds to a target risk in animals, 
which is 1/1,000 (i.e., BMRm/100, where 
BMRm is set to 0.10). Under these assump-
tions, the RfD based on the SNCD was 
derived by linear extrapolation; that is, a lin-
ear model was drawn from the UERSNCD 
down to zero extra risk, and the RfD was 
estimated as the dose corresponding to the 
target risk of 1/1,000 according to the linear 
model. Comparisons between RfDs based on 
the application of a UF of 100 to both the 
BMDL10 and the NOAEL with RfDs based 
on the SNCD, as described above, are tabu-
lated in Table 3 and presented in graphical 
form in Figure 6. The medians of the ratios 
between RfDs based on the BMDL10 and the 
SNCD1.0 or SNCD0.67 both equal 1; the vari-
ability in the ratios across data sets is, how-
ever, generally less for the BMDL10:SNCD0.67 
ratio than for BMDL10:SNCD1.0 (Table 3). 
The median of the ratio between RfDs based 
on the NOAEL and RfDs based on the 
SNCDs is 1.2 and 1.5 for SNCD0.67 and 
SNCD1.0, respectively (case 1); the variabil-
ity in this ratio is much greater than for the 
BMDL10:SNCD ratios (Table 3).
Results for the subset of data composed 
of only data sets with the lowest NOAEL in 
each NTP technical report (case 2; Table 3) are 
similar to those presented above for all data sets 
(case 1). The BMDL10- versus SNCD-based 
RfD ratios tend to increase slightly for data sets 
that are more informative regarding responses 
in the low-dose region (case 4 vs. case 3), 
whereas the opposite holds for the NOAEL- 
versus SNCD-based RfD ratios (case 3 vs. 
case 4; Table 3). Considering the more infor-
mative data sets only (case 4), the median of all 
four ratios is approximately 1.
Model dependence and impact of sample 
size. To assess model dependence, results 
from the Hill model can be contrasted with 
those derived from the Weibull model [see 
Supplemental Material, Section 3 (http://
dx.doi.org/10.1289/ehp.1003327)]. Model 
dependence is minimal for both the BMDL 
and the SNCD0.67 in both subsets of the 
data considered. Although this represents a 
somewhat limited analysis of model depen-
dence, it does suggest that sensitivities of 
these two PoDs to the choice of model are 
similar. An increased sample size is bene  ficial 
for both the SNCD and the BMDL, so that 
larger experiments will lead to higher human 
Figure 3. Ratios between different PoDs and the SNCD1.0. The dotted vertical lines indicate a ratio of 1.
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Figure 4. Ratios between different PoDs and the SNCD0.67. The dotted vertical lines indicate a ratio of 1.
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exposure guidelines when using either of these 
PoDs; a greater benefit was observed for the 
SNCD-based exposure guideline relative to 
the BMDL-based exposure guideline (see 
Supplemental Material, Section 4).
Discussion
In this article we address issues related 
to establishing human exposure guide-
lines for chemicals, comparing both exist-
ing (the NOAEL and the BMDL) and new 
(the SNCD) PoDs for determining an RfD. 
Empirical comparisons among RfDs based 
on these three PoDs were made using the 
complete NTP 2-year carcinogenesis bio-
assay database, including 786 quantal dose–
response data sets suitable for dose–response 
modeling. The SNCD concept is an objec-
tive approach for determining the lowest dose 
that can be used as a PoD for determining a 
human exposure guideline, without having 
the signal overwhelmed by noise.
The selection of the most appropriate 
BMR to use in the application of the BMD 
approach has usually been addressed by com-
paring NOAEL and BMDL values over several 
data sets. The EFSA (2009a) pointed out in its 
scientific opinion on the BMD that for an indi-
vidual NOAEL, the residual risk might be less 
than or greater than the BMR values (i.e., 1%, 
5%, or 10%) normally considered in appli-
cations of the BMD concept; this point was 
illustrated by calculating the upper bound on 
the extra risk at the NOAEL for a limited selec-
tion of substances that have been previously 
evaluated. The present study provides a much 
more comprehensive picture of the possible 
level of residual at the NOAEL by calculating 
a UERNOAEL across a large number of data sets 
(the UERNOAEL estimated in this study trans-
lates to the BMR as it is used in the BMD 
approach). Specifically, we showed that the 
median of the UERNOAEL was slightly higher 
than 10% (Table 1), whereas the UERSNCD 
was 7% or 18%, depending on the stringency 
of the definition of the SNCD [i.e., whether 
the SNR is set equal to 1 (SNCD1.0) or 0.67 
(SNCD0.67), the former being more stringent]. 
Some of the results presented here can 
be contrasted with those from earlier studies 
Table 3. Ratios between RfDs based on the 
BMDL10 and NOAEL, and RfDs based on the SNCD, 
expressed as medians and lower 5th (P05) and 
upper 95th (P95) percentiles across the n data sets 
considered.
RfD ratioa Caseb n Median P05 P95
RfDBMDL10: 
RfDSNCD1.0
1 439 1.0 0.50 1.6
2 106 0.98 0.51 1.8
3 217 0.89 0.39 1.7
4 222 1.0 0.75 1.5
RfDBMDL10: 
RfDSNCD0.67
1 665 1.0 0.66 1.3
2 124 1.0 0.66 1.1
3 243 0.93 0.42 1.6
4 422 1.1 0.84 1.1
RfDNOAEL: 
RfDSNCD1.0
1 439 1.5 0.41 7.6
2 106 1.4 0.41 8.6
3 217 2.4 0.65 9.3
4 222 1.0 0.38 3.2
RfDNOAEL: 
RfDSNCD0.67
1 665 1.2 0.39 7.7
2 124 1.2 0.40 9.9
3 243 2.2 0.42 11
4 422 1.0 0.39 3.3
aThe RfDs based on the BMDL10 and NOAEL were estab-
lished by dividing the respective PoD by a UF of 100; 
the RfD based on the SNCD was established by linear 
extrapolation from the UERSNCD, and it corresponds 
to a target extra risk of 1/1,000. bDifferent subsets of 
the 786 data sets were considered, as represented by 
the following cases: Case 1: All data sets adequate 
for dose–response modeling [according to the crite-
ria in Supplemental Material, Section 1 (http://dx.doi.
org/10.1289/ehp.1003327)], and for which an SNCD 
was derived. Case 2: Data sets with the lowest NOAEL 
in each selected technical report included in case 1. 
Case 3: Data sets in case 1 including at most one dose 
for which the observed extra risk was > 0 and ≤ 0.2; the 
observed extra risk at a given dose, i, was calculated as 
[xi/ni – p(0)]/[1 – p(0)], where p(0) is the point estimate of 
the background risk. Case 4: Data sets in case 1 includ-
ing more than one dose for which the observed extra risk 
was > 0 and ≤ 0.2. 
Table 2. Ratios between different PoDs and the SNCD, expressed as medians and lower 5th (P05) and 
upper 95th (P95) percentiles across the n data sets considered.
PoD:SNCD1.0 PoD:SNCD0.67
PoD Casea n Median P05 P95 n Median P05 P95
BMDL01 1 439 0.082 0.0089 0.31 665 0.17 0.020 0.50
2 106 0.062 0.0086 0.30 124 0.14 0.015 0.47
3 217 0.043 0.0069 0.34 243 0.071 0.013 0.70
4 222 0.14 0.020 0.27 422 0.23 0.048 0.48
BMDL05 1 439 0.34 0.046 1.3 665 0.71 0.11 2.3
2 106 0.30 0.045 1.3 124 0.63 0.078 2.3
3 217 0.19 0.036 1.2 243 0.31 0.069 1.8
4 222 0.55 0.10 1.3 422 1.1 0.25 2.4
BMDL10 1 439 0.62 0.096 2.8 665 1.3 0.22 4.9
2 106 0.58 0.095 2.8 124 1.2 0.17 4.9
3 217 0.34 0.076 2.2 243 0.59 0.14 3.9
4 222 1.0 0.22 2.8 422 2.1 0.49 5.1
NOAEL 1 439 1.0 0.31 3.1 665 1.9 0.56 5.2
2 106 1.0 0.34 3.3 124 1.7 0.51 4.8
3 217 1.0 0.28 3.2 243 1.6 0.42 5.0
4 222 1.1 0.33 3.0 422 2.1 0.63 5.4
aDifferent subsets of the 786 data sets were considered, as represented by the following cases. Case 1: All data sets 
adequate for dose–response modeling [according to the criteria in Supplemental Material, Section 1 (http://dx.doi.
org/10.1289/ehp.1003327)] and for which an SNCD was derived. Case 2: Data sets with the lowest NOAEL in each 
selected technical report included in case 1. Case 3: Data sets in case 1 including at most one dose for which the 
observed extra risk was > 0 and ≤ 0.2; the observed extra risk at a given dose, i, was calculated as [xi/ni – p(0)]/[1 – p(0)], 
where p(0) is the point estimate of the background risk. Case 4: Data sets in case 1 including more than one dose for 
which the observed extra risk was > 0 or ≤ 0.2. 
Figure 5. Correlations between differences in dose and UER. (A) Correlation between NOAEL:SNCD1.0 
and UERNOAEL:UERSNCD1.0 based on the 439 data sets (circles) for which an SNCD1.0 was derived. The 
median dose and risk ratio, shown by the vertical and horizontal lines, are both 1. (B) Correlation between 
BMDL10:NOAEL and UERBMDL10:UERNOAEL, based on the 439 data sets (circles) for which an SNCD1.0 was 
derived. Observe that the UER at BMDL10 is 0.10. The median dose and risk ratio are 0.71 and 0.73, respec-
tively (if all 786 data sets adequate for modeling are considered, the median dose and risk ratio are both 
0.93). Circles in B situated along the curved line correspond to data sets for which the Hill coefficient η = 1; 
the other circles correspond to data sets for which η > 1.
1.0
0.5
0
–0.5
–1.0
–1.5
1.0
0.5
0
–0.5
–1.0
–1.5
L
o
g
1
0
 
(
U
E
R
N
O
A
E
L
:
U
E
R
S
N
C
D
1
.
0
)
Log10 (NOAEL:SNCD1.0) Log10 (BMDL10:NOAEL)
L
o
g
1
0
 
(
U
E
R
B
M
D
L
1
0
:
U
E
R
N
O
A
E
L
)
–1.5 –1.0 –0.5 –3 –2 –1 01 01 0.5Sand et al.
1772  v o l u m e  119 | n u m b e r 12 | December 2011  •  Environmental Health Perspectives
that have compared the BMD and NOAEL. 
For developmental toxicity data, BMDLs cor-
responding additional risks of 1%, 5%, and 
10%, estimated using a Weibull model, were 
lower than the NOAEL, on average. These 
results were based on 407 data sets demonstrat-
ing significant trends in risk with increasing 
dose. The mean and median NOAEL:BMDL10 
ratios were 2.9 and 2.0, respectively (Allen 
et al. 1994a); this finding indirectly suggests 
that the average risk at the NOAEL is > 10%. 
Risk assessment methods designed specifically 
for develop  mental toxicity testing have also 
been applied. Allen et al. (1994b) found that 
a BMDL corresponding to an additional risk 
of 5% resembled the NOAEL on average; 
based on 253 developmental toxicity data sets, 
the median NOAEL:BMDL05 ratio in that 
study was 0.96. Other studies have assessed 
the risk at the NOAEL in more direct terms. 
Gaylor (1992) calculated the observed risk at 
the NOAEL using the proportion of affected 
fetuses at the NOAEL, minus the propor-
tion of affected fetuses in the control group, 
essentially a point estimate of additional risk 
using a model-free approach. That analysis was 
based on 236 develop  mental toxicity data sets 
reported in the scientific literature. The risk 
at the NOAEL for either dead/resorbed or 
malformed fetuses ranged from 0 to 4.5% 
and exceeded 1% in about 25% of the cases. 
In a theoretical analysis of how large the risk 
may be at the NOAEL, Leisenring and Ryan 
(1992) reported that the average extra risks 
at the NOAEL varied between 3% and 21%, 
depending on the experimental designs and 
shapes of Weibull dose–response curves con-
sidered. An important difference between 
the present analysis and those conducted 
by Gaylor (1992) and Leisenring and Ryan 
(1992) is that we considered an upper bound 
on the risk at the NOAEL, in addition to a 
point estimate of risk. For continuous data, 
analysis of 395 NTP data sets (rat and mouse 
data on body weight, liver and kidney weight, 
and red blood cell counts) indicated that the 
BMDL05 (defined as a 5% change in the mean 
response relative to background) was close to 
the NOAEL at median (Bokkers and Slob 
2007; EFSA 2009a). 
The SNCD as defined in this article was 
higher than other reference points that have 
been suggested for risk assessment (Table 2, 
Figures 3, 4). In particular, the BMDL01, but 
also the BMDL05, was generally lower than 
the SNCD. Depending on the stringency 
of the definition of the SNCD, the median 
BMDL10:SNCD ratio was either 0.6 or 1.3, 
for an SNR of 1 or 0.67, respectively. The pri-
mary motivation for proposing the use of the 
SNCD as a PoD for low-dose risk assessment 
is to start from the lowest possible point on 
the dose–response curve for which the signal 
in the data can be reliably detected. With both 
the BMDL01 and BMDL05 being below the 
SNCD, they may not be appropriate as default 
PoDs. The BMDL01 may be particularly prob-
lematic is this regard, being uniformly lower 
than the SNCD in virtually all cases consid-
ered; viewed another way, the upper bound 
of extra risk at the SNCD (UERSNCD) was 
also higher than 1% for virtually all the data 
(Figure 2). The median NOAEL:SNCD ratio 
was 1 when the SNCD was defined in terms 
of an SNR of 1.0 (Table 2, Figure 5).
For some of the 786 data  sets, the 
SNCD1.0 (44%), SNCD0.67 (15%), BMDL10 
(12%), and BMD10 (31%) were outside 
the experi  mental dose range. The relatively 
high proportion of data sets (12–44%) for 
which these quantities were not within the 
experimental dose range suggests that many 
data sets may in fact provide a quite limi-
ted basis for quantitative risk assessment; 
such situations can become more apparent 
when dose–response modeling approaches 
are applied compared with when a NOAEL 
approach is used.
The automated model selection approach 
used in the present study resulted in the use 
of a Hill coefficient η = 1 in most cases [see 
Supplemental Material, Section 1 (http://
dx.doi.org/10.1289/ehp.1003327)]. This is a 
reflection of the information value in the data 
regarding the Hill coefficient and should not 
be seen as evidence that the dose response in 
the low-dose region is in fact linear; rather, it 
indicates only that data could be adequately 
described by models that assumed linear-
ity. This type of model selection approach 
is embraced in the BMD method. In the 
automated modeling approach, we decided 
to use an objective method for determining 
the appropriate degree of parameterization 
because the three-parameter model was not 
suitable for all data sets. The width of the CI, 
for example, can change appreciably, depend-
ing on whether a two- or three-parameter 
model is used. More specifically, the CI may 
be tighter when a model with fewer param-
eters is used, and this can become relevant for 
the SNCD as well as the BMDL.
The standard UFs used in risk assess-
ment may need to be modified when the 
PoD is defined on the basis of the BMD. For 
example, it has been discussed that an extra 
UF may be needed when using the BMD 
approach because this PoD, by design, cor-
responds to a non  zero risk equal to the BMR 
(U.S. EPA 1995). This argument is presented 
with the implicit assumption that the NOAEL 
is a true “no effect level.” However, because 
the median UER associated with the NOAEL 
Figure 6. Comparison of different RfDs based on different PoDs. (A) The median RfDBMDL10:RfDSNCD1.0 ratio is 1; 50% of the ratios are > 1. (B) The median 
RfDBMDL10:RfDSNCD0.67 ratio is 1; 66% of the ratios are > 1. (C) The median RfDNOAEL:RfDSNCD1.0 ratio is 1.5; 72% of the ratios are > 1. 
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was close to 10%, it could also be argued that 
the standard UFs might be as appropriate 
for the BMDL10 as they are for the NOAEL 
because the resultant RfDs would, on average, 
provide a similar level of protection.
If the dose–response curve is linear below 
the PoD, application of the default UF of 100 
to the BMDL10 translates to a target (extra) 
risk of 1/1,000. Using this as a basis, we devel-
oped a modified RfD approach using the 
SNCD as the PoD: Specifically, the RfD is 
calculated as the dose corresponding to a target 
extra risk of 1/1,000 by linear extrapolation 
from the UERSNCD. Implicit in this approach 
is the application of a data-specific UF to the 
SNCD in order to arrive at the RfD. We used 
a target risk of 1/1,000 because it calibrates to 
applying the default UF of 100 to the more 
traditional PoDs (the NOAEL and BMDL10). 
This choice of target risk provided a starting 
point under which the different approaches 
could be compared. Further development of 
the SNCD concept could involve alterna-
tive target risks, based on public health con-
siderations (for performing risk reduction 
using the SNCD as starting point), as well 
as alternative low-dose extrapolation models. 
Although not considered herein, animal-to-
human extrapolation may also be regarded 
as a separate step after the SNCD-based 
PoD has been established. In the interim, 
the median RfDBMDL10:RfDSNCD1.0 ratio 
was approximately 1 (Table 3). The median 
RfDNOAEL:RfDSNCD1.0 ratio was > 1, except 
for the more informative data sets (Table 3).
Historically, the most common argument 
put forward in favor of the BMD as a PoD is 
the explicit recognition of sample size, which 
the NOAEL accounts for in an inappropri-
ate manner. As the sample size increases, the 
uncertainty in the BMD will decrease, result-
ing in a less conservative RfD. This is clearly 
beneficial from a regulatory point of view 
because larger experiments then may allow 
higher (less conservative) exposure guidelines. 
However, the practical consequence of this 
theoretical advantage of the BMD approach, 
at the level of a resulting RfD, depends on 
how much the sample size is increased and 
possibly on the selected BMR. The SNCD 
will also be affected by an increasing sample 
size (theoretically, it will be decreased), and 
as shown in this article, it will also be affected 
by the “value of information” embedded in 
the data in the lower dose region (case 3 vs. 
case 4; Tables 1, 2). In case of a sub  linear or 
linear dose–response below the SNCD, linear 
extrapolation from the SNCD will result in a 
less conservative RfD, as data quality increases. 
In the hypothetical case of a supra  linear dose–
response below the SNCD, however, the 
opposite applies. In any event, the extent to 
which low-dose extrapolation is necessary is 
reduced because the SNCD decreases as data 
quality increases. The impact of sample size on 
the SNCD is illustrated and discussed in detail 
in Supplemental Material, Section 4 (http://
dx.doi.org/10.1289/ehp.1003327).
The empirical results presented in this arti-
cle are based on cancer bio  assay data from the 
NTP. Because these results focus on a specific 
toxicological end point assessed under proto-
cols that follow a relatively standard experi-
mental design, their generalizability to other 
end points is constrained. To address this limi-
tation, and to further explore the SNCD con-
cept, we plan to repeat the empirical analyses 
conducted in this study using other databases, 
beginning with the NTP database on high-
throughput in vitro screens, which involves a 
wide range of biological end points reflecting 
different toxicity pathways. High-throughput 
screens are of particular interest in this regard 
because they represent one of the cornerstones 
of the U.S. EPA’s strategic plan for evaluating 
the toxicity of environmental agents in the 
future (Firestone et al. 2010; Krewski et al. 
2011). Although we discuss the SNCD con-
cept for quantal dose–response data in this 
article, the concept is also applicable to con-
tinuous dose–response data. Methodological 
extensions of the SNCD concept to accom-
modate continuous or polychotomous data 
will be pursued in future research.
Conclusions
Using NTP 2-year carcinogenesis bio  assay data 
as the basis for an empirical study of the prop-
erties of different PoDs for establishing human 
exposure guidelines to environmental agents, 
we found that the median risk associated with 
the traditional PoD for risk assessment—the 
NOAEL—is close to 10%. Given the type 
of study design covered in the analysis, this 
observation suggests that the application of 
standard UFs to the BMDL10 will provide a 
similar level of protection, at the median, as 
the application of those same factors to the 
NOAEL, when deriving an RfD. The SNCD 
proposed here also appears to warrant consid-
eration as a reference point in risk assessment 
because it provides an objective estimate of 
the lowest dose that may reasonably serve as a 
PoD for low-dose risk assessment. Our analysis 
suggests that use of extra risks < 10% may not 
be appropriate as default BMRs because cor-
responding BMDLs were generally below the 
SNCD. For high-quality data sets (i.e., with 
larger sample size and/or more information in 
the low-dose range), the SNCD will decrease, 
which reduces the extent of extrapolation nec-
essary. Using the default UF of 100 as a basis 
and noting that the median risk associated 
with the NOAEL is close to 10%, we suggest a 
target risk of 1/1,000 for derivation of an RfD 
from the SNCD by linear extrapola  tion. At 
the median, this approach provided the same 
RfD as the BMDL10 divided by the default 
UF of 100. Although a linear extrapolation 
model and a target risk of 1/1,000 were used 
for derivation of the SNCD-based human 
exposure guideline, other models for low-dose 
extrapolation, and target risks relevant from a 
public health point of view, may be considered 
as the SNCD concept is further developed.
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